Menu
Menu
We have been the earliest investor with dozens of teams that have dared to pursue their vision—creating and leading new markets, and shaping the future.
Meet the companies that inspire us every day.
Gen1E is a drug development company. Gen1E has an AI platform to screen for treatments of rare inflammatory diseases such as ARDS, ALS, Cyctic Fibrosis. The CEO has been working on the p38 pathway which is the key driver of inflammation at a number of companies over the past 20 years. The Company has 21 compounds in their pipeline, with matching indications. Currently, Gen1E has cleared Phase I with its lead compound to treat ARDS, the leading cause of death related to Covid 19 infections.
Nigel Duffy
Founder
Simon Wilkinson
Head of Engineering
Ryan McMahon
Chief of Staff
Four of the companies our team co-founded produced over $1.7 billion of market cap from 2 IPOs and 2 acquisitions.
The Clear investment team has funded over 70 companies, 90% as the first investors, and has had 54 exits valued at a $85 billion market cap.
Before we became VCs, we had already founded 5 successful companies.
CLEAR®, CLEAR VENTURES®, CLEAR VENTURE PARTNERS™, CLEARVP™, CLEAR VENTURE MANAGEMENT™, CLEAR INDUSTRY PARTNERS™, and the logos associated therewith are trademarks of Clear Venture Management LLC and are protected by trademark laws of the United States and other countries. All other product and company names are trademarks or registered trademarks of their respective companies
Get the Clear Ventures Newsletter
